News | April 07, 2008

Human Study Demonstrates Safety Of Polymer-Free DES

April 8, 2008 - The first-in-man study funded by MIV Therapeutics Inc. (MIV) showed that MIV's VESTAsync stents performed as well or better than commercially available drug stent combinations, while using 60 percent less drug, according to data presented at the American College of Cardiology conference in Chicago, IL.

Based on the belief that one of the causes of restenosis arises from the materials used to construct the stents, particularly the polymer (plastic) that holds the drug component, MIV demonstrated the safety of a revolutionary new type of drug-eluting vascular stent that uses materials found naturally in the human body, and does not employ polymers.

In the Brazilian study, conducted by Alexandre Abizaid, M.D., Ph.D. at Institute Dante Pazzanese of Cardiology in Sao Paolo, investigators implanted stents in 15 patients and measured the extent of restenosis at four and nine months using two independent measures. The two time points are chosen to allow for healing (four months) and subsequent inflammatory or cell-proliferative responses (nine months).

The two methods used by Dr. Abizaid were intravascular ultrasound, an imaging technique for blood vessels similar to ultrasound in other parts of the body, and quantitative coronary angiography, which uses a radioactive tracer injected into the heart to detect blockages through an X-ray camera positioned outside the body.

Researchers measured volumetric obstruction with the ultrasound, and late-lumen loss with the angiography. Volumetric obstruction relates to the percentage of the stent volume that has filled, while lumen loss measures the reduction, in millimeters, of the free path through the stent area at its narrowest.

Researchers found no statistically significant narrowing of blood vessels inside the VESTASync stent at nine months compared to the results of these patients at four months. Both volumetric obstruction and late lumen loss were comparable with restenosis measures for conventional drug-eluting stents. Significantly, investigators found no evidence of incomplete stent apposition (a measure of incomplete attachment of the stent to the blood vessel), no stent-related thrombosis (blood clot), and no major adverse coronary events over the study period.

Dr. Costa, who presented the data, commented, "Our nine month data are very encouraging and reaffirm our positive findings at four months. What is remarkable is these results were obtained with 60 percent less drug delivered from an ultra-thin 0.6-micron coating that is entirely polymer-free."

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init